![European Commission Approves Symtuza® for the Treatment of HIV-1 In Adults and Adolescents in Europe](https://mv.ecuo.org/wp-content/uploads/sites/4/2017/09/European-Commission-Approves-Symtuza-for-the-Treatment-of-HIV-1-In-Adults-and-Adolescents-in-Europe-1-270x189_c.png)
European Commission Approves Symtuza® for the Treatment of HIV-1 In Adults and Adolescents in Europe
Janssen-Cilag International NV (Janssen) today announced that the European Commission has approved the use of Symtuza® (darunavir/cobicistat/emtricitabine/tenofovir alafenamide [D/C/F/TAF]), a once-daily darunavir-based single-tablet regimen (STR), for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents aged 12 years and older with ...